James Freddo

James is a veteran biotech executive and consultant with more than 20 years of experience leading clinical development teams, designing oncology drug development and regulatory strategies, and conducting clinical trials. He has held senior roles in large and small pharmaceutical companies and has co-founded multiple biotechnology startups. After acting as a Consultant Chief Medical Officer, he joined the Board of Directors for Ignyta where he served until its acquisition by Roche in 2018. James was formerly the Chief Medical Officer and Senior Vice President, Drug Development and a member of the Board of Directors at Anadys Pharmaceuticals, which was acquired by Roche in 2011. Prior to joining Anadys Pharmaceuticals, he served at Pfizer, holding the positions of Vice President, Clinical Site Head, and Development Site Head and, prior to that, Executive Director and leader of Oncology Clinical Development. Prior to Pfizer, he held a variety of senior management positions at Wyeth-Ayerst Research, in the oncology, infectious diseases, and transplantation immunology therapeutic areas. He has also served as a member of the Board of Directors for InfuSystems, Inc., a public healthcare products and services company. James received an M.D. degree from the University of North Carolina, Chapel Hill; completed his residency training at University of California, San Diego; and returned to Chapel Hill for his fellowship training in gynecologic oncology.